Form Type and Filing Date: This is an 8-K Current Report filed by LabCorp Holdings Inc. on September 22, 2026, reporting events as of the same date. Item 7.01 - Regulation FD Disclosure: The filing indicates that Item 7.01 (Regulation FD Disclosure) is being reported, though the specific disclosure content is not fully visible in the provided document excerpt. Company Information: LabCorp…

Our analysis rates this filing BEARISH. LabCorp faces a HIGH concern level (7.2/10) driven by a confirmed material negative event with existential implications for the core business. The September 21, 2026 CMS release of preliminary 2027-2029 Clinical Laboratory Fee Schedule rates represents a…

Concern level: HIGH (7.2/10). Key factors: Three new high-severity risks identified with average severity 8.0/10, including existential threat to core business model from CMS rate cuts; Confirmed material negative event: CMS released preliminary 2027-2029 Clinical Laboratory Fee Schedule rates characterized by company as 'steep annual payment cuts that threaten patient access to laboratory…

Notable risk changes: CMS released preliminary 2027-2029 Clinical Laboratory Fee Schedule rates on Sept 21, 2026 - company characterizes as 'steep annual payment cuts' that threaten patient access. This is a confirmed material negative event, not a hypothetical risk. Company is reaffirming prior guidance despite this headwind, suggesting significant operational pressure.; Company deferring quantification of CMS rate…